Novelion Therapeutics (NVLN) Reports Q4 Loss of $1.72
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results
March 15, 2017 7:00 AM EDTCompany Reiterates FY 2017 Total Net Product Sales Expected to be Between $155 and $165 million Global Expansion Plans for Metreleptin Opportunity Underway
VANCOUVER, British Columbia, March 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (Novelion or the Company), today reported preliminary financial results for the fourth quarter and year ended December 31, 2016 and provided an overview of recent business highlights.
The... More
